A Randomised Placebo-Controlled Study of Purified Anthocyanins on Cognition in Individuals at Increased Risk for Dementia.

Autor:	Aarsland D; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway; Department of Old Age Psychiatry (DA), King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK., Khalifa K; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway; Department of Old Age Psychiatry (DA), King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK; The Faculty of Health Sciences (KK), University of Stavanger, Stavanger, Norway. Electronic address: khalifakhadija11@yahoo.com., Bergland AK; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway., Soennesyn H; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway., Oppedal K; Department of Electrical Engineering and Computer Science (KO), University of Stavanger, Stavanger, Norway., Holteng LBA; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine (LBAH, AN), University of Bergen, Bergen, Norway., Oesterhus R; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway; The Hospital Pharmacy Enterprise of Western Norway (RO), Bergen, Norway., Nakling A; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine (LBAH, AN), University of Bergen, Bergen, Norway., Jarholm JA; Department of Neurology (AJ, TF), Akershus University Hospital, Lørenskog, Norway., de Lucia C; Centre for Age-Related Medicine (DA, KK, AKB, HS, LBAH, RO, AN, CDL), Stavanger University Hospital, Stavanger, Norway; Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience (CDL), King's College London, London, UK., Fladby T; Department of Neurology (AJ, TF), Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine (HB, TF), University of Oslo, Oslo, Norway., Brooker H; Medical School (HB), University of Exeter, Exeter, UK; Ecog Pro Ltd. (HB, CB), Bristol, UK., Dalen I; Section of Biostatistics, Department of Research (ID), Stavanger University Hospital, Stavanger, Norway., Ballard C; Medical School (HB), University of Exeter, Exeter, UK.
Jazyk:	angličtina
Zdroj:	The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry [Am J Geriatr Psychiatry] 2023 Feb; Vol. 31 (2), pp. 141-151. Date of Electronic Publication: 2022 Oct 18.
DOI:	10.1016/j.jagp.2022.10.002
Abstrakt:	Importance: Identifying nutritional compounds which can reduce cognitive decline in older people is a hugely important topic. Objective: To study the safety and effect of anthocyanins in maintaining cognitive functioning in people at increased risk for dementia. Design, Setting, and Participants: Participants (206 individuals, aged 60-80 years) diagnosed with either mild cognitive impairment (MCI) or two or more cardiometabolic disorders (i.e., diabetes, hypertension, obesity) were enrolled at three different centres in Norway. Intervention: Participants were randomly assigned to four capsules with a total of 320 mg/d of naturally purified anthocyanins or placebo 1:1 for 24 weeks. Main Outcomes and Measures: The primary outcome was the Quality of Episodic Memory composite measure (0-100) from an online cognitive test battery CogTrack, which was administered at baseline and monthly for the next 24 weeks. Secondary outcomes included other cognitive scores from the CogTrack battery. We applied mixed effects models with a baseline test score, group, time and their interaction as fixed effects, as well as other predefined baseline covariates. The primary comparison was the group difference at week 24 based on a modified intention-to-treat principle. Results: The primary analysis did not show a significant group difference at 24 weeks (78.2 versus 76.8; adjusted mean difference 1.4 (95% confidence interval -0.9-3.7); effect size 0.15; p = 0.23). However, there was a significant difference in slopes during weeks 8-24 (p = 0.007); the anthocyanin group improved while the placebo group worsened. No differences were found for the secondary cognitive outcomes. Anthocyanin capsules were well-tolerated and safe to use. Conclusion: Anthocyanin supplementation for 24 weeks was safe and well tolerated in people with MCI or cardiometabolic disorders. We found no significant group difference in episodic memory at the end of the study but statistically significant differences in slopes. Further studies are warranted to explore whether anthocyanins supplementation can reduce cognitive decline in people at increased risk of dementia. Trial Registration: ClinicalTrials.gov, (Identifier NCT03419039). http://www. Clinicaltrials: gov/, NCT03419039. (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu